IDH1 and central nervous system cancer: Although this perspective may include some subjective assessment, it suggests that the primary candidates for such monitoring might be limited to cases where complete resection is deemed challenging, such as tumors involving multiple lobes with unresectable enhancing components, or recurrent IDH-mutant gliomas.